INmune Bio Statistics
Total Valuation
INmune Bio has a market cap or net worth of $68.06 million. The enterprise value is $31.41 million.
Important Dates
The last earnings date was Thursday, August 7, 2025, after market close.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
INmune Bio has 26.59 million shares outstanding. The number of shares has increased by 20.28% in one year.
| Current Share Class | 26.59M |
| Shares Outstanding | 26.59M |
| Shares Change (YoY) | +20.28% |
| Shares Change (QoQ) | +3.57% |
| Owned by Insiders (%) | 17.01% |
| Owned by Institutions (%) | 22.77% |
| Float | 17.09M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,286.73 |
| Forward PS | 19.00 |
| PB Ratio | 2.23 |
| P/TBV Ratio | 2.23 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 628.27 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.20, with a Debt / Equity ratio of 0.02.
| Current Ratio | 4.20 |
| Quick Ratio | 4.14 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -218.21 |
Financial Efficiency
Return on equity (ROE) is -168.34% and return on invested capital (ROIC) is -69.11%.
| Return on Equity (ROE) | -168.34% |
| Return on Assets (ROA) | -55.08% |
| Return on Invested Capital (ROIC) | -69.11% |
| Return on Capital Employed (ROCE) | -136.49% |
| Revenue Per Employee | $2,273 |
| Profits Per Employee | -$2.52M |
| Employee Count | 22 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -63.71% in the last 52 weeks. The beta is 0.98, so INmune Bio's price volatility has been similar to the market average.
| Beta (5Y) | 0.98 |
| 52-Week Price Change | -63.71% |
| 50-Day Moving Average | 4.19 |
| 200-Day Moving Average | 6.28 |
| Relative Strength Index (RSI) | 41.85 |
| Average Volume (20 Days) | 2,972,051 |
Short Selling Information
The latest short interest is 5.98 million, so 22.51% of the outstanding shares have been sold short.
| Short Interest | 5.98M |
| Short Previous Month | 5.53M |
| Short % of Shares Out | 22.51% |
| Short % of Float | 35.02% |
| Short Ratio (days to cover) | 1.42 |
Income Statement
In the last 12 months, INmune Bio had revenue of $50,000 and -$55.51 million in losses. Loss per share was -$2.52.
| Revenue | 50,000 |
| Gross Profit | 50,000 |
| Operating Income | -39.72M |
| Pretax Income | -37.74M |
| Net Income | -55.51M |
| EBITDA | n/a |
| EBIT | -39.72M |
| Loss Per Share | -$2.52 |
Full Income StatementBalance Sheet
The company has $33.37 million in cash and $451,000 in debt, giving a net cash position of $32.92 million or $1.24 per share.
| Cash & Cash Equivalents | 33.37M |
| Total Debt | 451,000 |
| Net Cash | 32.92M |
| Net Cash Per Share | $1.24 |
| Equity (Book Value) | 28.87M |
| Book Value Per Share | 1.09 |
| Working Capital | 27.45M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$32.20 million and capital expenditures -$706,000, giving a free cash flow of -$32.90 million.
| Operating Cash Flow | -32.20M |
| Capital Expenditures | -706,000 |
| Free Cash Flow | -32.90M |
| FCF Per Share | -$1.24 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -79,430.00% |
| Pretax Margin | -111,016.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
INmune Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -20.28% |
| Shareholder Yield | -20.28% |
| Earnings Yield | -86.28% |
| FCF Yield | -51.14% |
Analyst Forecast
The average price target for INmune Bio is $9.53, which is 272.27% higher than the current price. The consensus rating is "Buy".
| Price Target | $9.53 |
| Price Target Difference | 272.27% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 537.27% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
INmune Bio has an Altman Z-Score of 0.32 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.32 |
| Piotroski F-Score | 3 |
